Study: Seneschal 2025, Dermatology and Therapy
Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies
Citation
Seneschal J, Wolkerstorfer A, Desai SR, et al (2025). Dermatology and Therapy. PubMed id 40156697.
Cards that cite this study (2)
Each card gives its own wording for who was tested, how and what was found.
- Vitiligo Tier B moderate
B The same 674 patients, pooled post hoc (n=674)
Subgroup analysis by age, sex, Fitzpatrick skin type and other traits.
At week 52, 50.3% of those applying ruxolitinib cream throughout reached the facial score target; responses were seen across subgroups including Fitzpatrick skin type. The abstract gives no numbers for dark skin types.
As recorded in this card: Seneschal J, Wolkerstorfer A, Desai SR et al (2025), Dermatology and Therapy, [primary]
Note: Descriptive, post hoc; not a Black-population analysis.
- Vitiligo, spread, starting age and treatment options Tier B thin
B 674 people aged 12 or over with non-segmental vitiligo (two phase 3 trials, TRuE-V1 and V2); how many were Black is not in the abstract (n=674)
Post hoc pooled descriptive analysis of two randomised vehicle-controlled trials of 1.5% ruxolitinib cream.
At week 52, 50.3% (176 of 350) who used the cream throughout reached 75% improvement in facial vitiligo score, against 28.2% (46 of 163) who switched from vehicle cream after week 24. Responses were seen across age, sex and Fitzpatrick skin type, with similar side-effect rates; the abstract gives no figure per skin type.
As recorded in this card: Seneschal J, Wolkerstorfer A, Desai SR, et al (2025), Dermatology and Therapy, [primary]
Note: Descriptive subgroup analysis, so it does not show the cream works equally in every skin type. Funding not stated in the abstract; funding not checked. The American Academy of Dermatology page acknowledges support from Incyte Dermatology.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.